 The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US74bn of peak sales in 2023, according to a research report from Credit Suisse, This is in comparison to US102bn of readouts in 2022 and US78bn in 2021, excluding COVID-19-related treatments. The report also found that a record proportion of the 2023 readouts, approximately 40, will come from line extensions where a drug is already approved for use in a different disease setting. 